Efficacy of miltefosine compared with glucantime for the treatment of cutaneous leishmaniasis: a systematic review and meta-analysis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Cutaneous leishmaniasis (CL) is most common form of leishmaniasis and is characterized by ulcerative skin lesions. The objective of this study was to conduct a systematic review and meta-analysis of clinical trials that compared the efficacy of miltefosine and glucantime for the treatment of CL. We searched the following databases: Cochrane, PubMed, Embase, Scopus, Web of Science, ProQuest, Cochrane Central Register of Controlled Trials, International Clinical Trials Registry Platform search portal of World Health Organization, Sid, Irandoc, Magiran, and clinicaltrials.gov. We used keywords including “miltefosine,” “glucantime,” and “Leishmania.” The quality of studies was assessed using the Cochrane risk of bias tool. A random-effects model was employed for the analysis. We assessed heterogeneity by the chi-square test and the I2 index statistic. When heterogeneity was present, meta-regression analyses were performed. The Egger method was used to assess publication bias; when it was significant, the trim-and-fill method was used to test and adjust for publication bias. A total of 1,570 reports were identified, of which 10 studies were included in the meta-analysis. In the meta-analysis, there was no significant difference between the efficacy of miltefosine and glucantime; however, subgroup analysis showed that, regarding parasite species other than Leishmania braziliensis, miltefosine was significantly superior to glucantime (intention to treat; relative risk, 1.15; 95% confidence interval, 1.01 to 1.32). In the meta-regression, only the glucantime injection type was significant at the p=0.1 level. The Egger test found statistically significant publication bias; however, including the 3 missing studies in the trim-and-fill analysis did not change the results. This meta-analysis found that miltefosine seems to be more effective than glucantime, at least in species other than L. braziliensis, for treating CL.
Abstract
Cutaneous leishmaniasis (CL) is most common form of leishmaniasis and is characterized by ulcerative skin lesions. The objective of this study was to conduct a systematic review and meta-analysis of clinical trials that compared the efficacy of miltefosine and glucantime for the treatment of CL. We searched the following databases: Cochrane, PubMed, Embase, Scopus, Web of Science, ProQuest, Cochrane Central Register of Controlled Trials, International Clinical Trials Registry Platform search portal of World Health Organization, Sid, Irandoc, Magiran, and clinicaltrials.gov. We used keywords including “miltefosine,” “glucantime,” and “Leishmania.” The quality of studies was assessed using the Cochrane risk of bias tool. A random-effects model was employed for the analysis. We assessed heterogeneity by the chi-square test and the I2 index statistic. When heterogeneity was present, meta-regression analyses were performed. The Egger method was used to assess publication bias; when it was significant, the trim-and-fill method was used to test and adjust for publication bias. A total of 1,570 reports were identified, of which 10 studies were included in the meta-analysis. In the meta-analysis, there was no significant difference between the efficacy of miltefosine and glucantime; however, subgroup analysis showed that, regarding parasite species other than Leishmania braziliensis, miltefosine was significantly superior to glucantime (intention to treat; relative risk, 1.15; 95% confidence interval, 1.01 to 1.32). In the meta-regression, only the glucantime injection type was significant at the p=0.1 level. The Egger test found statistically significant publication bias; however, including the 3 missing studies in the trim-and-fill analysis did not change the results. This meta-analysis found that miltefosine seems to be more effective than glucantime, at least in species other than L. braziliensis, for treating CL.
참고문헌 (43)
- Reithinger R, "Cutaneous leishmaniasis", Lancet Infect Dis, 7, pp.581~596 (2007)
- Alvar J, "Leishmaniasis worldwide and global estimates of its incidence", PLoS One, 7, pp.e35671~ (2012)
- "Leishmaniasis"[URL]
- Khan SJ, "Cutaneous leishmaniasis in Pakistan", Dermatol Online J, 11, pp.4~ (2005)
- Rahman SB, "Laboratory profile in patients of cutaneous leishmaniasis from various regions of Pakistan", J Coll Physicians Surg Pak, 13, pp.313~316 (2003)
- Mujtaba G, "Cutaneous leishmaniasis in Multan, Pakistan", Int J Dermatol, 37, pp.843~845 (1998)
- Jones TC, "Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis brasiliensis", J Infect Dis, 156, pp.73~83 (1987)
- Miranda Lessa M, "Mucosal leishmaniasis : epidemiological and clinical aspects", Braz J Otorhinolaryngol, 73, pp.843~847 (2007)
- Turetz ML, "Disseminated leishmaniasis : a new and emerging form of leishmaniasis observed in northeastern Brazil", J Infect Dis, 186, pp.1829~1834 (2002)
- Soto J, "Current situation and future of antileishmanial therapy in Colombia", Biomedica, 26(Suppl 1), pp.194~206 (2006)
- Rahman SB, "Miltefosine in cutaneous leishmaniasis", J Coll Physicians Surg Pak, 17, pp.132~135 (2007)
- Vélez I, "Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis", Am J Trop Med Hyg, 83, pp.351~356 (2010)
- Salam N, "Leishmaniasis in the Middle East: incidence and epidemiology", PLoS Negl Trop Dis, 8, pp.e3208~ (2014)
- Herwaldt BL, "Recommendations for treating leishmaniasis with sodium stibogluconate(Pentostam)and review of pertinent clinical studies", Am J Trop Med Hyg, 46, pp.296~306 (1992)
- Croft SL, "Drug resistance in leishmaniasis", Clin Microbiol Rev, 19, pp.111~126 (2006)
- Croft SL, "Current scenario of drug development for leishmaniasis", Indian J Med Res, 123, pp.399~410 (2006)
- González U, "Interventions for American cutaneous and mucocutaneous leishmaniasis", Cochrane Database Syst Rev, pp.CD004834~ (2009)
- Santos JB, "Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous leishmaniasis ulcers : a randomized, double-blind, placebo-controlled study", J Infect Dis, 190, pp.1793~1796 (2004)
- Arevalo I, "Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis", Clin Infect Dis, 44, pp.1549~1554 (2007)
- Kedzierski L, "Leishmaniasis : current treatment and prospects for new drugs and vaccines", Curr Med Chem, 16, pp.599~614 (2009)
- Ouellette M, "Leishmaniasis : drugs in the clinic, resistance and new developments", Drug Resist Updat, 7, pp.257~266 (2004)
- Asilian A, "Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime®) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime®) alone for the treatment of cutaneous leishmaniasis", Int J Dermatol, 43, pp.281~283 (2004)
- Hadighi R, "Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites", PLoS Med, 3, pp.e162~ (2006)
- Alvar J, "Chemotherapy in the treatment and control of leishmaniasis", Adv Parasitol, 61, pp.223~274 (2006)
- Berman JD, "Development of miltefosine for the leishmaniases", Mini Rev Med Chem, 6, pp.145~151 (2006)
- Romero GA, "Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate", Am J Trop Med Hyg, 65, pp.456~465 (2001)
- Unger A, "Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil", Am J Trop Med Hyg, 80, pp.574~579 (2009)
- Machado PR, "Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial", PLoS Negl Trop Dis, 4, pp.e912~ (2010)
- Sundar S, "Oral miltefosine for Indian visceral leishmaniasis", N Engl J Med, 347, pp.1739~1746 (2002)
- Soto J, "Miltefosine for new world cutaneous leishmaniasis", Clin Infect Dis, 38, pp.1266~1272 (2004)
- Soto J, "Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent", Clin Infect Dis, 33, pp.E57~E61 (2001)
- Van Thiel PP, "Miltefosine treatment of Leishmania major infection : an observational study involving Dutch military personnel returning from northern Afghanistan", Clin Infect Dis, 50, pp.80~83 (2010)
- Mohebali M, "Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis(ZCL)by a randomized clinical trial in Iran", Acta Trop, 103, pp.33~40 (2007)
- Soto J, "Oral miltefosine to treat new world cutaneous leishmaniasis", Lancet Infect Dis, 7, pp.7~ (2007)
- Chrusciak-Talhari A, "Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania(Viannia)guyanensis in Manaus, Brazil", Am J Trop Med Hyg, 84, pp.255~260 (2011)
- Rubiano LC, "Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children", J Infect Dis, 205, pp.684~692 (2012)
- Khatami A, "Miltefosine in treatment of cutaneous leishmaniasis: a randomized controlled trial: P-31", Br J Dermatol, 167, pp.e23~ (2012)
- Soto J, "Efficacy of miltefosine for Bolivian cutaneous leishmaniasis", Am J Trop Med Hyg, 78, pp.210~211 (2008)
- Asilian A, "Comparing the effects of topical miltefosine and glucantime in treatment of cutaneous leishmaniasis", J Isfahan Med Sch, 31, pp.2257~2263 (2014)[DOI]
- Reveiz L, "Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update", PLoS One, 8, pp.e61843~ (2013)
- Higgins JP, "The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials", BMJ, 343, pp.d5928~ (2011)
- Higgins JP, "Quantifying heterogeneity in a meta-analysis", Stat Med, 21, pp.1539~1558 (2002)
- Dorlo TP, "Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients", Antimicrob Agents Chemother, 52, pp.2855~2860 (2008)